Treatment of Restless Leg Syndrome (RLS) Augmentation With Ecopipam, a D1 Specific Antagonist
Status:
Unknown status
Trial end date:
2018-10-15
Target enrollment:
Participant gender:
Summary
This is an exploratory, double blinded cross-over study of the D1 antagonist ecopipam treat
patients currently having dopamine agonist induced augmentation in restless legs syndrome.
Each arm is 6 weeks composed of an unforced titration up to 100mg/day separated by a 2-week
wash-out period. Efficacy points will include the IRLS, augmentation scales, sleep scales,
clinical impressions and fatigue/mood scales.